(redirected from gram-negative)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to gram-negative: gram-positive, gram-negative folliculitis
GNGrand National (Buick Regal)
GNGuinea (country code, top level domain)
GNGraphic Novel
GNGram-Negative (bacteria)
GNGreat Northern (former Danish telegraph company, now known as GN Store Nord A/S)
GNGendarmerie Nationale (French: National Police; Niger)
GNGood Night
GNGreat Neck (Long Island, New York)
GNGuide Number (photography)
GNGrammar Nazi
GNGreat Northern Railway
GNGonadotropin (hormone)
GNGnosis (game Werewolf the Apocalypse; White Wolf)
GNGross Negligence (law)
GNGrand Nationals (NASCAR auto racing)
GNGalvaneal (steel)
GNGuidance Note (instruction and advice)
GNGender Neutral
GNGary Numan (singer)
GNGraduate Nurse
GNGeneral Notes
GNGood Neighbors
GNGovernment of Nunavut (Canada)
GNAir Gabon (IATA airline code)
GNGolgi Network
GNGroup Ad-Hoc Network
GNGerman Navy
GNGaseous Nitrogen
GNGrid North
GNGround Network
GNGuantanamo to New York (routing designation)
GNGeneral Nurse
GNGlenbard North (Illinois)
GNGastroenterology Nursing (journal)
GNGénération Nouvelle (French: New Generation)
GNGundam Nucleus
GNGrouping Network
GNGay Nerds (website and forum)
References in periodicals archive ?
One of the most important issue facing hospitals and health care settings is the increased number of ESBL producing bacteria, most of these bacteria have been isolated from critical patients.16,17 Here, we reported ESBL producers in 44.4% of Gram-negative isolates.
Supported by the Innovative Medicine Initiative (IMI), the new GNA NOW (Gram-Negative Antibiotic NOW) project, led by Evotec SE and managed by Lygature, will work on the development of novel antibacterial agents to battle antimicrobial resistance in gram-negative bacteria.
The rapid spread of acquired Metallo-beta-lactamases (MBLs) among major Gram-negative pathogens is an emerging threat and a matter of great concern worldwide.
Doctors have not had a new treatment for gram-negative bacteria in the last 50 years, and no potential drugs have entered clinical trials since 2010.
The objective of this R01 grant is to provide tools that can facilitate therapeutic discovery for Gram-negative bacterial pathogens, including carbapenem-resistant Enterobacteriaceae, multi-drug resistant Acinetobacter baumannii and/or MDR Pseudomonas aeruginosa.
Delegates attending the Superbugs & Superdrugs conference next year in 2019 will have the exclusive opportunity of hearing from Genentech's Senior Scientist Michael Koehler, who is set to speak and present at the 21st annual event on "Optimized Arylomycins represent a new class of Gram-Negative Antibiotics."
All these patients illustrate the challenges inherent to this problem.6 The current study was planned to explore the prevalence of resistance in gram-negative pathogens isolated from chronic kidney diseases and renal transplant patients.
Achaogen has other programs in early and late preclinical stages of development focused on other MDR gram-negative infections and additional disease areas.
Non-fermenting Gram-negative Bacilli other than Pseudomonas aeruginosa and Acinetobacter Spp.
Now, a team of researchers may have figured out a way of getting antibiotics that normally don't work on Gram-negative bacteria inside those cells.
Of the 592 blood cultures, 42 (7.8%) yielded gram-negative bacteria, 28 (67%) from YGH and 14 (33%) from the 2 private hospitals.
The following bacteria were identified in cultures from the non-diabetic group: Staphylococcus aureus (gram-positive cocci) in 8 cultures (53.3%); coagulase-negative Staphylococci (CNS, grampositive cocci) in 4 cultures (26.7%); Klebsiella pneumoniae (gram-negative bacilli) in 1 culture (6.7%) and more than one species of bacterium in 2 cultures (13.3%).